US Stock MarketDetailed Quotes

PVLA Palvella Therapeutics

Watchlist
  • 11.800
  • -0.200-1.67%
Close Dec 24 13:00 ET
  • 11.800
  • 0.0000.00%
Post 17:01 ET
164.37MMarket Cap5.99P/E (TTM)

Palvella Therapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(FY)Dec 31, 2022
Assets
Current assets
Cash, cash equivalents and short term investments
--6.25M
-54.21%7.35M
--16.05M
-Cash and cash equivalents
--6.25M
-54.21%7.35M
--16.05M
Other current assets
--144K
-57.96%198K
--471K
Total current assets
--6.39M
-54.32%7.55M
--16.52M
Non current assets
Total non current assets
--0
--0
--0
Total assets
--6.39M
-54.32%7.55M
--16.52M
Liabilities
Current liabilities
Payables
--1.02M
-70.58%936K
--3.18M
-accounts payable
--1.02M
-70.58%936K
--3.18M
Current accrued expenses
--1.11M
-35.71%1.08M
--1.68M
Other current liabilities
--185K
6.29%169K
--159K
Current liabilities
--2.73M
-59.18%2.36M
--5.78M
Non current liabilities
Derivative product liabilities
--1.07M
-32.35%1.01M
--1.5M
Preferred securities outside stock equity
--70.6M
0.00%70.6M
--70.6M
Other non current liabilities
--8.86M
-75.16%8.05M
--32.42M
Total non current liabilities
--80.53M
-23.77%79.67M
--104.52M
Total liabilities
--83.27M
-25.63%82.03M
--110.3M
Shareholders'equity
Share capital
--0
--0
--0
-common stock
--0
--0
--0
Retained earnings
---78.84M
19.68%-76.3M
---94.99M
Paid-in capital
--1.96M
49.63%1.82M
--1.22M
Total stockholders'equity
---76.87M
20.57%-74.48M
---93.78M
Total equity
---76.87M
20.57%-74.48M
---93.78M
Currency Unit
USD
USD
USD
(Q1)Mar 31, 2024(FY)Dec 31, 2023(FY)Dec 31, 2022
Assets
Current assets
Cash, cash equivalents and short term investments --6.25M-54.21%7.35M--16.05M
-Cash and cash equivalents --6.25M-54.21%7.35M--16.05M
Other current assets --144K-57.96%198K--471K
Total current assets --6.39M-54.32%7.55M--16.52M
Non current assets
Total non current assets --0--0--0
Total assets --6.39M-54.32%7.55M--16.52M
Liabilities
Current liabilities
Payables --1.02M-70.58%936K--3.18M
-accounts payable --1.02M-70.58%936K--3.18M
Current accrued expenses --1.11M-35.71%1.08M--1.68M
Other current liabilities --185K6.29%169K--159K
Current liabilities --2.73M-59.18%2.36M--5.78M
Non current liabilities
Derivative product liabilities --1.07M-32.35%1.01M--1.5M
Preferred securities outside stock equity --70.6M0.00%70.6M--70.6M
Other non current liabilities --8.86M-75.16%8.05M--32.42M
Total non current liabilities --80.53M-23.77%79.67M--104.52M
Total liabilities --83.27M-25.63%82.03M--110.3M
Shareholders'equity
Share capital --0--0--0
-common stock --0--0--0
Retained earnings ---78.84M19.68%-76.3M---94.99M
Paid-in capital --1.96M49.63%1.82M--1.22M
Total stockholders'equity ---76.87M20.57%-74.48M---93.78M
Total equity ---76.87M20.57%-74.48M---93.78M
Currency Unit USDUSDUSD
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.